-
Eisai China won the 2020 Economic Contribution Award-Outstanding Contribution Award for Output Efficiency
Time of Update: 2021-10-22
Suzhou, October 8, 2021/PRNewswire/ - On September 28, Eisai China won the 2020 Economic Contribution in the 2021 Suzhou Municipal Government’s exchange activities with multinational companies and the awarding ceremony of the honorary title of Suzhou’s foreigners Award-Outstanding Contribution Award for Output Benefits, in recognition of the remarkable, iconic and leading contribution to Suzhou's economic development .
-
Domestically-made innovative drugs are speeding up overseas, and many new drugs are about to be launched abroad
Time of Update: 2021-10-22
S. Food and Drug Administration (FDA) has also accepted Baiyueze® for the treatment of marginal zone lymphoma (MZL) adults who have previously received at least one CD20-directed therapy The patient’s New Indication Marketing Application (sNDA) and granted priority review qualifications .
-
Hengrui wins the first review with 2 billion anesthetics
Time of Update: 2021-10-22
Author: Bai YuA few days ago, Hengrui Pharmaceuticals issued an announcement stating that the company has been approved for inhalation sevoflurane for imitation of the 4 types of applications and is deemed to have been reviewed.
-
Weijian Pharmaceuticals and China Rare Disease Alliance strategically cooperate to help the construction of a healthy ecology for rare diseases
Time of Update: 2021-10-22
Boao, Hainan, October 8, 2021/PRNewswire/ - September 30, 2021 (Hainan·Boao), Hong Kong Weijian Pharmaceutical Group ("Vaijian Pharmaceutical") and China Rare Disease Alliance formally signed a five-y
-
The exclusive varieties are missing!
Time of Update: 2021-10-21
Prior to this (September 30), the Guangdong Provincial Pharmaceutical Exchange Center issued the "Guangdong Union Diclofenac and other 153 drug groups with volume procurement documents (draft for comments)", involving 153 varieties, including 3 blood products, 4 basic infusions and There are 146 other drugs, of which 50 are exclusive varieties (after grouping, now 51), see the attached table at the end of the article .
-
CDE publicly solicits opinions on 2 technical guidelines
Time of Update: 2021-10-21
On October 11, the CDE official website publicly solicited opinions on two technical guidelines, namely, the technical guidelines for the clinical research and development of rare disease drugs and the technical guidelines for the design of long-acting granulocyte colony stimulating factors to prevent infection after chemotherapy (draft for comments) .
-
Sanofi clopidogrel aspirin tablets approved in China
Time of Update: 2021-10-21
Public information shows that this is an anti-platelet single-tablet compound (SPC), which is suitable for preventing atherosclerotic thrombosis in adult patients with acute coronary syndrome who have taken clopidogrel and aspirin at the same time .
Chinese expert consensus on antiplatelet therapy of clopidogrel/aspirin single-tablet compound preparation[J].
-
The third quarterly report intensive disclosure period!
Time of Update: 2021-10-21
It is understood that there are two main factors driving the growth of Yanan Bikang’s performance: First, the new energy products of Jiujiujiu Technology, a subsidiary of Yan’an Bikang, are affected by market demand, the release of production capacity, and the increase in market prices, resulting in profit compared with last year.
-
After October 15, the prices of medicines in many places will be greatly reduced
Time of Update: 2021-10-21
For example, Shandong Province recently issued the "Notice on the Implementation of the Results of the Fifth Batch of National Organizations' Centralized Purchase of Drugs", requiring all public medical institutions and military medical institutions in Shandong Province to participate in voluntary participation from October 15, 2021.
-
Children's drug concept stocks are booming, and many R&D and production companies report net profits increase by more than 30%
Time of Update: 2021-10-21
Poinsettia released a semi-annual performance report on the evening of July 29, stating that the operating income for the first half of 2021 was about 953 million yuan; the net profit attributable to shareholders of listed companies was about 1.
-
The disclosure of the third quarterly report is imminent, who are the ones that are expected to be happy for the performance of the sci-tech innovation board drug companies?
Time of Update: 2021-10-21
According to incomplete statistics, as of October 11, 13 sci-tech innovation board companies have disclosed their performance forecasts for the first three quarters, of which 10 stocks are pre-happy, accounting for more than 70%, and the overall performance is relatively good .
-
With local pharmaceutical companies investing heavily in innovation, R&D costs have soared
Time of Update: 2021-10-21
31 billion yuan, of which the R&D expenditure in the pharmaceutical manufacturing industry will reach 784.
For example, as listed biomedical companies on the Sci-tech Innovation Board continued to increase R&D investment in the first half of the year, the total R&D investment amount has reached 5.
-
2021 Veeva China Business and Medical Summit is about to open
Time of Update: 2021-10-21
Shanghai, October 13, 2021/PRNewswire/ - Veeva Systems (NYSE: VEEV), a global life science industry-based solution provider based on the cloud computing model, officially announced that it will be in
-
Merck's new crown oral drug Molnupiravir submits EUA to FDA
Time of Update: 2021-10-21
On October 11, Merck announced that it had submitted an emergency authorization application (EUA) for the oral antiviral drug Molnupiravir (MK-4482) to the FDA .
If approved, Molnupiravir will become the first oral antiviral drug for COVID-19 .
-
Johnson & Johnson's blockbuster CD38 monoclonal antibody daratumomab subcutaneous injection approved in China
Time of Update: 2021-10-21
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn October 11, the official website of the State Food and Drug Administration showed that Johnson & Johnson's CD38 monoclonal antibody daratumomab injection (subcutaneous injection) has been approved for marketing by NMPA for the treatment of patients with primary light chain amyloidosis .
-
Under policy changes, chain drugstore giants are expected to undertake sustained high performance
Time of Update: 2021-10-21
In recent years, with the advancement of policies such as prescription outflows, public hospital reforms, medical insurance control fees, volume purchases, and "dual channels", the pharmaceutical retail industry has undergone tremendous changes, and the industry concentration has continued to increase.
-
12 products of China Resources Double Crane were awarded "2021 Excellent Product Brand in the Chemical and Pharmaceutical Industry"
Time of Update: 2021-10-21
At the meeting, the "2021 Chemical Pharmaceutical Industry Excellent Enterprise and Excellent Product Brand Cultivation Plan" list was released, and 12 products under China Resources Shuanghe were rated as "Excellent Product Brands" .
-
With the accelerated innovation of pharmaceutical companies, the AI drug research and development track is getting hotter and hotter
Time of Update: 2021-10-21
For a long time, new drugs have been characterized by difficult design, high cost, and time-consuming. On average, the industry’s previous research and development of a new drug required "10 years an
-
incredible! Qilu's 2 blockbuster varieties have been approved for listing
Time of Update: 2021-10-21
Today (October 11), the official website of NMPA showed that Qilu Pharmaceutical's ceftazidime avibactam sodium for injection and sunitinib malate capsules were approved for marketing .
According to data from Meinenet, the sales of terminal sunitinib in China's public medical institutions will exceed 500 million yuan in 2020, a year-on-year increase of 44.
-
The market for inhalation preparations is booming, and many pharmaceutical companies have completed billions of yuan in financing during the year!
Time of Update: 2021-10-21
Public information shows that Changxi Pharmaceutical is a clinical stage biomedical company for the discovery, development and industrialization of new drugs that seriously affect the quality of human daily life, including respiratory diseases, and has patent-protected dry powder preparation technology and Efficient and convenient inhaler technology .
